The India launch of Eli Lilly's popular weight-loss drug Mounjaro has triggered a huge wave of patient enquiries about its ...

In an interview, the US pharmaceuticals giant’s international chief says Australia has made no progress in making life easier for medicine developers.

The implications for Eli Lilly and Novo Nordisk seem pretty clear: The immediate removal of a rival for the massive revenues ...

The drugmaker said one patient became ill after being treated with its experimental weight-loss drug, danuglipron.

Eli Lilly benefits from rising cash flow and a strong pipeline, yet elevated pricing versus peers limits near-term gains. See ...

Eli Lilly's foray into telehealth shows the emerging importance virtual care platforms are playing in the rising popularity ...

Guggenheim lowered the firm’s price target on Eli Lilly (LLY) to $928 from $973 and keeps a Buy rating on the shares. The firm is updating its ...

Eli Lilly said on Tuesday it had sued two mass compounders for selling unapproved products that contain tirzepatide, the main ...

To what extent will health clinics go to keep selling in-demand weight-loss drugs now that the FDA has outlawed cheaper ...

Lately, however, Eli Lilly's stock has cooled. Shares have been essentially flat since July 2024. The market for GLP-1 ...

Some industries have escaped these moves by the administration, at least for now. One of them is the pharmaceutical industry.

Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...